$IMUX
Immunic Inc

2018 Q3 Form 10-Q Financial Statement

#000128077618000079 Filed on August 07, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2018 Q2 2017 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.460M $4.260M $2.720M
YoY Change -16.61% 56.62% 1.12%
% of Gross Profit
Research & Development $1.410M $2.157M $9.834M
YoY Change -85.45% -78.07% 43.39%
% of Gross Profit
Depreciation & Amortization $204.0K $200.0K $229.0K
YoY Change -5.56% -12.66% -53.27%
% of Gross Profit
Operating Expenses $1.805M $2.670M $12.55M
YoY Change -85.72% -78.72% 31.46%
Operating Profit -$1.805M -$2.670M -$12.55M
YoY Change -85.72% -78.72% 31.46%
Interest Expense $110.0K $160.0K $170.0K
YoY Change -42.11% -5.88% 112.5%
% of Operating Profit
Other Income/Expense, Net $8.000K $0.00 $142.0K
YoY Change -94.94% -100.0% 82.05%
Pretax Income -$11.94M -$12.68M -$12.41M
YoY Change -4.33% 2.18% 31.05%
Income Tax
% Of Pretax Income
Net Earnings -$1.797M -$2.670M -$12.41M
YoY Change -85.6% -78.48% 31.04%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$11.26M -$11.96M -$11.71M
COMMON SHARES
Basic Shares Outstanding 42.37M shares 42.37M shares 42.21M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q3 2018 Q2 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $17.80M $31.10M $76.20M
YoY Change -73.19% -59.19% 3.53%
Cash & Equivalents $17.80M $31.12M $76.15M
Short-Term Investments
Other Short-Term Assets $1.300M $1.500M $1.900M
YoY Change -18.75% -21.05% 5.56%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $19.06M $32.65M $78.06M
YoY Change -71.95% -58.18% 3.48%
LONG-TERM ASSETS
Property, Plant & Equipment $890.0K $2.059M $2.430M
YoY Change -60.83% -15.27% -19.38%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $37.00K $97.00K $182.0K
YoY Change -70.63% -46.7% 0.0%
Total Long-Term Assets $927.0K $2.156M $2.612M
YoY Change -61.34% -17.46% -18.27%
TOTAL ASSETS
Total Short-Term Assets $19.06M $32.65M $78.06M
Total Long-Term Assets $927.0K $2.156M $2.612M
Total Assets $19.99M $34.80M $80.68M
YoY Change -71.59% -56.86% 2.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.131M $1.075M $1.076M
YoY Change 15.29% -0.09% 21.31%
Accrued Expenses $4.552M $7.185M $6.147M
YoY Change -36.49% 16.89% 78.74%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.691M $8.299M $7.292M
YoY Change -30.88% 13.81% 63.02%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
Total Long-Term Liabilities $45.00K $49.00K $46.00K
YoY Change -2.17% 6.52% 283.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.691M $8.299M $7.292M
Total Long-Term Liabilities $45.00K $49.00K $46.00K
Total Liabilities $5.736M $8.348M $7.338M
YoY Change -30.72% 13.76% 63.61%
SHAREHOLDERS EQUITY
Retained Earnings -$335.0M -$323.0M -$268.9M
YoY Change 19.05% 20.13% 21.17%
Common Stock $4.000K $4.000K $4.000K
YoY Change 0.0% 0.0% -92.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$20.80M -$18.97M $73.34M
YoY Change
Total Liabilities & Shareholders Equity $19.99M $34.80M $80.68M
YoY Change -71.59% -56.86% 2.6%

Cashflow Statement

Concept 2018 Q3 2018 Q2 2017 Q2
OPERATING ACTIVITIES
Net Income -$1.797M -$2.670M -$12.41M
YoY Change -85.6% -78.48% 31.04%
Depreciation, Depletion And Amortization $204.0K $200.0K $229.0K
YoY Change -5.56% -12.66% -53.27%
Cash From Operating Activities -$13.08M -$12.36M -$10.15M
YoY Change 38.85% 21.77% 15.08%
INVESTING ACTIVITIES
Capital Expenditures -$270.0K -$180.0K -$140.0K
YoY Change 68.75% 28.57% 250.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $10.00K
YoY Change -100.0% -87.5%
Cash From Investing Activities -$270.0K -$180.0K -$130.0K
YoY Change 58.82% 38.46% -425.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 20.00K 10.00K -210.0K
YoY Change -111.11% -104.76% -104.66%
NET CHANGE
Cash From Operating Activities -13.08M -12.36M -10.15M
Cash From Investing Activities -270.0K -180.0K -130.0K
Cash From Financing Activities 20.00K 10.00K -210.0K
Net Change In Cash -13.33M -12.53M -10.49M
YoY Change 36.44% 19.45% 145.67%
FREE CASH FLOW
Cash From Operating Activities -$13.08M -$12.36M -$10.15M
Capital Expenditures -$270.0K -$180.0K -$140.0K
Free Cash Flow -$12.81M -$12.18M -$10.01M
YoY Change 38.34% 21.68% 14.01%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
dei Document Period End Date
DocumentPeriodEndDate
2018-06-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001280776
CY2018Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
42369394 shares
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
VITAL THERAPIES INC
dei Trading Symbol
TradingSymbol
VTL
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1049000 USD
CY2018Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1075000 USD
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9141000 USD
CY2018Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7185000 USD
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10323000 USD
CY2018Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10743000 USD
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
78000 USD
CY2018Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
80000 USD
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
345915000 USD
CY2018Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
349392000 USD
CY2017Q4 us-gaap Assets
Assets
60384000 USD
CY2018Q2 us-gaap Assets
Assets
34801000 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
58121000 USD
CY2018Q2 us-gaap Assets Current
AssetsCurrent
32645000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
130000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
10000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
59991000 USD
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
76153000 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56901000 USD
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31116000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
16162000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-25785000 USD
CY2018Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
92.99
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
9498968 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42368864 shares
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42368998 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42368864 shares
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42368998 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
4000 USD
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
4000 USD
CY2017Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12401000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25002000 USD
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12677000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27068000 USD
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
91000 USD
CY2018Q2 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
39000 USD
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
59000 USD
CY2018Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
49000 USD
CY2017Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
229000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
564000 USD
CY2018Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
200000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
424000 USD
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.67
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.64
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3591000 USD
CY2018Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2272000 USD
us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2715000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5774000 USD
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4257000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8592000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
46000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
31000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1502000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2052000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-28000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-62000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
557000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
393000 USD
CY2017Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
169000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
266000 USD
CY2018Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
161000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
331000 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
CY2018Q2 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
27000 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
115000 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
60384000 USD
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
34801000 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10281000 USD
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
8299000 USD
CY2017Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
59000 USD
CY2018Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
49000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
37620000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-24000 USD
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
2000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-398000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2419000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-21060000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-25429000 USD
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-12407000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-332000 USD
us-gaap Net Income Loss
NetIncomeLoss
-25009000 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-12682000 USD
us-gaap Net Income Loss
NetIncomeLoss
-27070000 USD
CY2017Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
142000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
227000 USD
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
235000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
339000 USD
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
12549000 USD
us-gaap Operating Expenses
OperatingExpenses
25236000 USD
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
12917000 USD
us-gaap Operating Expenses
OperatingExpenses
27409000 USD
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12549000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-25236000 USD
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12917000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-27409000 USD
CY2017Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
229000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
483000 USD
CY2018Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
276000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
574000 USD
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
173000 USD
CY2018Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
410000 USD
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
108000 USD
CY2018Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
97000 USD
CY2017Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
6000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
7000 USD
CY2018Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
5000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
2000 USD
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
91000 USD
CY2018Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
39000 USD
CY2017Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-27000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-39000 USD
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
74000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8000 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
3000 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
218000 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
60000 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
25000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
405000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
334000 USD
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000 USD
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
us-gaap Share Based Compensation
ShareBasedCompensation
3360000 USD
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2018Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1220000 USD
CY2018Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1529000 USD
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
37500000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
37679000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
7000 USD
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12478000 USD
CY2018Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12802000 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2155000 USD
CY2018Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2059000 USD
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9834000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19462000 USD
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8660000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18817000 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-295953000 USD
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-323023000 USD
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4297119 shares
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.38
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
43926 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
6.74
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2459728 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.30
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.17
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
10957292 USD
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6083482 shares
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8499150 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.76
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.54
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
10531284 USD
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
8180579 shares
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
6.58
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.80
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.01
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2018Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
5095729 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y9M7D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M6D
CY2018Q2 vtl Issuance Of Securities Authorized Offering Amount Under Shelf Registration
IssuanceOfSecuritiesAuthorizedOfferingAmountUnderShelfRegistration
200000000 USD
CY2018Q2 vtl Maximum Aggregate Offering Priceof Securities Under Shelf Registration
MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration
200000000 USD
CY2018Q2 vtl Maximum Amount Of Common Stock That Can Be Issued Under At The Market Sales Agreement
MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement
60000000 USD
CY2018Q2 vtl Maximum Number Of Common Shares That Can Be Sold Under Shelf Registration Statement By Selling Shareholders
MaximumNumberOfCommonSharesThatCanBeSoldUnderShelfRegistrationStatementBySellingShareholders
2500000 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y3M11D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
134 shares
CY2017Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
40300000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
50044000 USD
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
26453000 USD
CY2017 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 USD
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 USD
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42207376 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37452655 shares
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42368973 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42368919 shares
CY2017Q4 vtl Accrued Clinical Costs
AccruedClinicalCosts
5377000 USD
CY2018Q2 vtl Accrued Clinical Costs
AccruedClinicalCosts
4503000 USD
vtl Common Stock Issuance Costs Included In Liabilities
CommonStockIssuanceCostsIncludedInLiabilities
150000 USD
vtl Common Stock Issuance Costs Included In Liabilities
CommonStockIssuanceCostsIncludedInLiabilities
99000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires us to make certain estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates and assumptions.</font></div></div>

Files In Submission

Name View Source Status
0001280776-18-000079-index-headers.html Edgar Link pending
0001280776-18-000079-index.html Edgar Link pending
0001280776-18-000079.txt Edgar Link pending
0001280776-18-000079-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vtl-063018xexhibit311.htm Edgar Link pending
vtl-063018xexhibit312.htm Edgar Link pending
vtl-063018xexhibit321.htm Edgar Link pending
vtl-063018xexhibit322.htm Edgar Link pending
vtl-20180630.xml Edgar Link completed
vtl-20180630.xsd Edgar Link pending
vtl-20180630_cal.xml Edgar Link unprocessable
vtl-20180630_def.xml Edgar Link unprocessable
vtl-20180630_lab.xml Edgar Link unprocessable
vtl-20180630_pre.xml Edgar Link unprocessable
vtl-63018x10q.htm Edgar Link pending